Yara A. Alorfi

Yara A. Alorfi

Auto-generated profile, based on publicly available information

Yara A. Alorfi

Internal Medicine Resident, Department of Internal Medicine, King Faisal Specialist Hospital and Research Centre, Jeddah, Saudi Arabia

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in International Journal of Medicine in Developing Countries
Verified
Journal Article
Closed access
PDF file
AAAlaa Alotaibi
Alaa Alotaibi
TMTurky Mal
Turky Mal
YAYara A. Alorfi
Yara A. Alorfi
DADoaa Alshabani
Doaa Alshabani
LALatifah Alzeer
Latifah Alzeer
JAJoud Alghamdi
Joud Alghamdi
Objective: This study aimed to investigate the potential correlation between adverse childhood experiences (ACEs) and the onset of migraines. Methods: This case-control study included 612 participants from Jeddah, Saudi Arabia. The case group consisted of 311 migraine patients from King Abdulaziz University Hospital, while 301 individuals without migraines formed the control group. Data were collected through structured surveys. Results: In the migraine group, 80.1% were women, with the highest prevalence among those aged 30 to 45 years (51.4%, p-value0.05, including experiences such as parental loss or household dysfunction. However, in the migraine group, parental loss was related to more severe headaches; median pain score = 9.0, p-value=0.047. Attacks of migraine significantly affect daily life, social activities, and professional activities, high frequency of drug intake (80.1%), and reduced working and academic efficiency. Conclusion: Although ACEs were not related to migraine prevalence, parental loss was associated with higher headache severity. These findings indicated the complexity of migraines and the need to incorporate psychosocial variables in their management. Further research into the genetic, environmental, and psychological influences that cause migraine is required.

23 October 2026 in Medicine
Verified
Journal Article
Open access
MAMohammed Alfawaz
Mohammed Alfawaz
DBDareen Bajamaan
Dareen Bajamaan
LALama Alghamdi
Lama Alghamdi
YAYara Alorfi
Yara Alorfi
SKSaud Khared
Saud Khared
SAShaima Altowairqi
Shaima Altowairqi
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) are increasingly prevalent liver diseases closely linked to obesity, type 2 diabetes mellitus, and cardiometabolic risk. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may improve hepatic and metabolic outcomes through weight reduction, improved glycemic control, and reductions in hepatic steatosis. This systematic review and meta-analysis aimed to evaluate the efficacy and safety of GLP-1 RAs in adults with MASLD or MASH. Methods: A systematic review and meta-analysis was conducted in accordance with PRISMA 2020 guidelines. PubMed, Web of Science, Scopus, Google Scholar, and the Cochrane Central Register of Controlled Trials were searched for English-language studies published between January 2019 and December 2025. Eligible studies included adults with MASLD or MASH treated with GLP-1 RAs and reporting hepatic, metabolic, or safety outcomes. Pooled estimates were calculated using random-effects models. Results: Nine studies involving 795 participants were included. GLP-1 RA therapy was associated with significant reductions in liver fat content (mean difference [MD]: −3.17; 95% CI: −4.06 to −2.29), body weight (MD: −4.68; 95% CI: −6.88 to −2.47), alanine aminotransferase (MD: −15.17; 95% CI: −21.29 to −9.05), aspartate aminotransferase (MD: −9.89; 95% CI: −13.65 to −6.13), and HbA1c (MD: −0.78; 95% CI: −1.07 to −0.49). Adverse events were more frequent with GLP-1 RAs, particularly nausea and vomiting, while serious adverse events did not differ significantly between groups. Conclusion: GLP-1 RAs are associated with meaningful improvements in hepatic steatosis, liver enzymes, body weight, and glycemic control in patients with MASLD or MASH. These findings support their potential role, particularly in patients with coexisting obesity or type 2 diabetes. However, further long-term, adequately powered trials are needed to clarify their effects on fibrosis regression, histological outcomes, and liver-related clinical events.